Michael Gold, MD
Gynecologic Oncology · Tulsa, OKNPI 1376511956
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,810 of the $15,089 with a category attached, or 78.3%. 20 manufacturers reported payments, led by Seagen Inc. at 33.8% of the total. 2025 is the largest year on record at $5,399, more than ten times the $160 reported in 2019.
Across 48 payments — averaging $314.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$5K
- AstraZeneca$5K
- GSK$3K
- Intuitive Surgical$2K
- Genmab U.S., Inc.$144
- Regeneron Healthcare Solutions, Inc.$122
- plus $444 from 14 others
Across 324 payments — averaging $8732.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$965K
- GSK$715K
- Genentech, Inc.$379K
- Tesaro, Inc.$278K
- AstraZeneca$256K
- Clovis Oncology, Inc.$78K
- plus $158K from 9 others
What the payments were for
- Consulting fees$11,81078%
- Travel & lodging$1,66411%
- Food & beverage$1,3349%
- Education$2692%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 5 | $5,106 |
| AstraZeneca | 8 | $4,810 |
| GSK | 2 | $2,816 |
| Intuitive Surgical | 10 | $1,647 |
| Genmab U.S., Inc. | 2 | $144 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Tesaro, Inc. | 1 | $113 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Johnson & Johnson | 3 | $51 |
| Novartis | 2 | $38 |
| Conmed Corporation | 1 | $28 |
| Merck | 1 | $26 |
| Novo Nordisk | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Clovis Oncology, Inc. | 3 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Millicent US Inc | 1 | $15 |
| AbbVie | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,461
- TIVDAK$125
- LIBTAYO$122
- ZEJULA$113
How this compares
$15,089 in reported general payments places this provider in the 75th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $152,851 |
| LynparzaOlaparib | 13 | $150,198 |
| Megestrol Acetate | 33 | $3,001 |
| Clobetasol Propionate | 37 | $1,837 |
| Ondansetron Hcl | 40 | $965 |
| Oxycodone Hcl | 65 | $713 |
| Prochlorperazine Maleate | 46 | $479 |
| Estradiol | 14 | $421 |
| Letrozole | 22 | $385 |
| Medroxyprogesterone Acetate | 17 | $247 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $192 |
| Gabapentin | 20 | $191 |
| Spironolactone | 12 | $189 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $180 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMekinist | $38 | $152,85112 claims |
| AstraZenecaLynparza | $4,810 | $150,19813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 gynecologic oncology providers in Oklahoma.
Other gynecologic oncology in Tulsa
- Daron StreetTulsa$55K
- Katherine MoxleyTulsa$44K
- Alfred JenkinsTulsa$994
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Roger PfeifferOwasso$7K
- Elizabeth EvansOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.